Efficacy of oseltamivir-peramivir combination therapy compared to oseltamivir monotherapy for Influenza A (H7N9) infection: a retrospective study

BackgroundSince the novel H7N9 avian influenza outbreak occurred in China in 2013, neuraminidase inhibitors (NAIs) such as oseltamivir and peramivir have been used as first-line drugs to treat the influenza virus infection. This study aimed to compare the efficacy of oseltamivir-peramivir combination therapy versus oseltamivir monotherapy.MethodsA retrospective study of 82 H7N9 confirmed patients was conducted by reviewing medical charts at the First Affiliated Hospital of ZheJiang University in China from April 1, 2013 to Feb 28, 2014. The patients’ clinical information was collected systematically, and we compared the virology and clinical data between oseltamivir monotherapy group (43 patients) and oseltamivir-peramivir combination group (39 patients).ResultsThe median duration from NAIs administration to H7N9 virus-negative in oseltamivir monotherapy group and oseltamivir-peramivir combination group was 6.50 and 7.00 days (p >0.05), respectively. The median decline of Day 2 to Day 0 (initiation of NAIs therapy) viral load was 0.00 and 0.69 log10 copies/μl (p >0.05) respectively in the monotherapy vs. combination therapy groups. The incidence of new Acute Respiratory Distress Syndrome during NAI administration was 63.89 and 77.78 % (p >0.05); while the mortality rates were 25.58 and 43.59 % (p >0.05) in the oseltamivir group vs. oseltamivir-peramivir group.ConclusionsOur results suggest that in adults with H7N9 virus infection, the use of oseltamivir-peramivir combination therapy was not superior to oseltamivir monotherapy.

• Publication year

  2015

• Venue

  BMC Infectious Diseases

• Publication date

  2015-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1186/s12879-016-1383-8PMID 26864456PMCID 4748590
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Human Infection with a Novel Avian-Origin Influenza A (H7N9) Virus.

  2018cited by this paper
• Epidemiology of human influenza A(H7N9) infection in Hong Kong.

  2017cited by this paper
• Characterization of drug-resistant influenza A(H7N9) variants isolated from an oseltamivir-treated patient in Taiwan.

  2015cited by this paper
• Epidemiology of human infections with avian influenza A(H7N9) virus in China.

  2014cited by this paper
• Oseltamivir-zanamivir combination therapy is not superior to zanamivir monotherapy in mice infected with influenza A(H3N2) and A(H1N1)pdm09 viruses.

  2014cited by this paper
• A prospective intervention study on higher-dose oseltamivir treatment in adults hospitalized with influenza a and B infections.

  2013cited by this paper
• Clinical findings in 111 cases of influenza A (H7N9) virus infection.

  2013cited by this paper
• Human infection with a novel avian-origin influenza A (H7N9) virus.

  2013cited by this paper
• Effect of double dose oseltamivir on clinical and virological outcomes in children and adults admitted to hospital with severe influenza: double blind randomised controlled trial

  2013cited by this paper
• Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance.

  2013influential reference
• Oseltamivir-zanamivir bitherapy compared to oseltamivir monotherapy in the treatment of pandemic 2009 influenza A(H1N1) virus infections.

  2012cited by this paper
• Influenza-associated pneumonia among hospitalized patients with 2009 pandemic influenza A (H1N1) virus--United States, 2009.

  2012cited by this paper
• Failure of combination oral oseltamivir and inhaled zanamivir antiviral treatment in ventilator- and ECMO-treated critically ill patients with pandemic influenza A (H1N1)v

  2011cited by this paper
• Effectiveness of oseltamivir on disease progression and viral RNA shedding in patients with mild pandemic 2009 influenza A H1N1: opportunistic retrospective study of medical charts in China

  2010influential reference
• Efficacy of Oseltamivir-Zanamivir Combination Compared to Each Monotherapy for Seasonal Influenza: A Randomized Placebo-Controlled Trial

  2010cited by this paper
• Triple Combination of Amantadine, Ribavirin, and Oseltamivir Is Highly Active and Synergistic against Drug Resistant Influenza Virus Strains In Vitro

  2010cited by this paper
• Effectiveness of antiviral treatment in human influenza A(H5N1) infections: analysis of a Global Patient Registry.

  2010cited by this paper
• Combinations of oseltamivir and peramivir for the treatment of influenza A (H1N1) virus infections in cell culture and in mice.

  2010influential reference
• Mining social mixing patterns for infectious disease models based on a two-day population survey in Belgium

  2009cited by this paper
• Effects of Double Combinations of Amantadine, Oseltamivir, and Ribavirin on Influenza A (H5N1) Virus Infections in Cell Culture and in Mice

  2009cited by this paper
• Oseltamivir-Ribavirin Combination Therapy for Highly Pathogenic H5N1 Influenza Virus Infection in Mice

  2007cited by this paper
• Duration of Influenza A Virus Shedding in Hospitalized Patients and Implications for Infection Control

  2007cited by this paper
• Amantadine-Oseltamivir Combination therapy for H5N1 Influenza Virus Infection in Mice

  2006cited by this paper
• Rimantadine and Oseltamivir Demonstrate Synergistic Combination Effect in an Experimental Infection with Type a (H3N2) Influenza Virus in Mice

  2006cited by this paper
• Anti-influenza virus activity of peramivir in mice with single intramuscular injection.

  2006cited by this paper
• Combination Treatment of Influenza A Virus Infections in Cell Culture and in Mice with the Cyclopentane Neuraminidase Inhibitor RWJ-270201 and Ribavirin

  2002cited by this paper
• Efficacy and Safety of the Oral Neuraminidase Inhibitor Oseltamivir in Treating Acute Influenza

  2000cited by this paper
• Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group.

  2000cited by this paper
• Independence of Evolutionary and Mutational Rates after Transmission of Avian Influenza Viruses to Swine

  1999cited by this paper
• Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group.

  1997cited by this paper
• Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections

  1997cited by this paper
• Patterns of shedding of myxoviruses and paramyxoviruses in children.

  1981cited by this paper

• Chinese expert consensus on the combined use of antiviral drugs for influenza.

  2025cites this paper
• Berberine Suppresses Influenza A Virus-Triggered Pyroptosis in Macrophages via Intervening in the mtROS-MAVS-NLRP3 Inflammasome Pathway

  2025cites this paper
• Antiviral strategies against influenza virus: an update on approved and innovative therapeutic approaches

  2025cites this paper
• Considerations when treating influenza infections with oseltamivir

  2024cites this paper
• The protective effects of a D-tetra-peptide hydrogel adjuvant vaccine against H7N9 influenza virus in mice

  2022cites this paper
• Influenza antivirals and their role in pandemic preparedness.

  2022cites this paper
• A systematic review of acute and emergency care interventions for adolescents and adults with severe acute respiratory infections including COVID-19 in low- and middle-income countries

  2022influential citation
• Quantification of Cytokine Storms During Virus Infections

  2021cites this paper
• Influenza A-associated severe pneumonia in hospitalized patients: Risk factors and NAI treatments.

  2020cites this paper
• Research progress on human infection with avian influenza H7N9

  2020cites this paper
• Prophylaxis of ferrets with nitazoxanide and oseltamivir combinations is more effective at reducing the impact of influenza a virus infection compared to oseltamivir monotherapy.

  2020cites this paper
• Oseltamivir and baloxavir: Dual treatment for rapidly developing ARDS on a patient with renal disease

  2020cites this paper
• A comparison of demographic, epidemiological and clinical characteristics of hospital influenza-related viral pneumonia patients

  2020cites this paper
• Effectiveness of Neuraminidase Inhibitors to Prevent Mortality in Laboratory-Confirmed Avian Influenza A H7N9 Patients.

  2020cites this paper
• Clinical outcomes of patients treated with intravenous zanamivir for severe influenza A(H1N1)pdm09 infection: a case report series

  2019cites this paper
• Novel Avian Influenza A Virus Infections of Humans

  2019cites this paper
• Factors associated with fatality due to avian influenza A(H7N9) infection in China.

  2019cites this paper
• Combination treatment with the cap-dependent endonuclease inhibitor baloxavir marboxil and a neuraminidase inhibitor in a mouse model of influenza A virus infection

  2018cites this paper
• Re-understanding anti-influenza strategy: attach equal importance to antiviral and anti-inflammatory therapies.

  2018cites this paper
• Fatty Acid Metabolism is Associated With Disease Severity After H7N9 Infection

  2018cites this paper
• Benefit of Early Initiation of Neuraminidase Inhibitor Treatment to Hospitalized Patients With Avian Influenza A(H7N9) Virus

  2018cites this paper
• Muscle weakness associated with H7N9 infection: report of two cases

  2018cites this paper
• Factors Associated With Prolonged Viral Shedding in Patients With Avian Influenza A(H7N9) Virus Infection

  2018cites this paper
• Antiviral Drugs for the Treatment and Prevention of Influenza

  2017cites this paper
• The in vivo efficacy of neuraminidase inhibitors cannot be determined from the decay rates of influenza viral titers observed in treated patients

  2017cites this paper
• Aerosol administration increases the efficacy of oseltamivir for the treatment of mice infected with influenza viruses.

  2017cites this paper
• The Hemagglutinin A Stem Antibody MEDI8852 Prevents and Controls Disease and Limits Transmission of Pandemic Influenza Viruses

  2017influential citation